Aurobindo Pharma Limited (BOM:524804)
1,115.45
-5.40 (-0.48%)
At close: Feb 21, 2025
Aurobindo Pharma Revenue
Aurobindo Pharma had revenue of 79.79B INR in the quarter ending December 31, 2024, with 8.53% growth. This brings the company's revenue in the last twelve months to 309.22B, up 10.85% year-over-year. In the fiscal year ending March 31, 2024, Aurobindo Pharma had annual revenue of 290.02B with 16.68% growth.
Revenue (ttm)
309.22B
Revenue Growth
+10.85%
P/S Ratio
n/a
Revenue / Employee
11.89M
Employees
26,015
Market Cap
647.68B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 290.02B | 41.46B | 16.68% |
Mar 31, 2023 | 248.55B | 14.00B | 5.97% |
Mar 31, 2022 | 234.55B | -13.19B | -5.32% |
Mar 31, 2021 | 247.75B | 16.76B | 7.26% |
Mar 31, 2020 | 230.99B | 35.35B | 18.07% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Reliance Industries | 9,398.38B |
Tata Consultancy Services | 2,520.82B |
HDFC Bank | 2,702.59B |
Bharti Airtel | 1,627.08B |
ICICI Bank | 1,755.26B |
Infosys | 1,635.60B |
State Bank of India | 3,409.52B |
Hindustan Unilever | 626.61B |
Aurobindo Pharma News
- 4 days ago - Pharma stocks drop up to 7% after Trump announces 25% tariff on imports - Business Upturn
- 4 days ago - Aurobindo shares fall 7% as US FDA issues 5 observations on pre-approval inspection for Andhra unit - Business Upturn
- 5 days ago - US FDA completes action with 5 observations for Aurobindo Pharma’s Eugia Steriles facility - Business Upturn
- 10 days ago - Pharma stocks rally: Aurobindo Pharma up 4.05%, Lupin jumps 3.81%, Biocon gains 2.80% at market open - Business Upturn
- 16 days ago - Aurobindo Pharma’s API Unit 2 in Telangana receives VAI classification from US FDA, EIR issued - Business Upturn
- 26 days ago - Aurobindo Pharma subsidiary’s facility receives EIR from US FDA with VAI classification - Business Upturn
- 4 weeks ago - Brokerage Report: CLSA expects India pharma market to grow at 8-9% in 2025, Dr. Reddy’s downgraded to ‘Underperform’, Aurobindo Pharma upgraded to ‘Outperform’ - Business Upturn
- 4 weeks ago - Pharma stocks: Glenmark up 1.57%, Glaxo gains 1.31%, Mankind Pharma declines 2.84% - Business Upturn